Product Wiki · Recalls · EU Safety Gate (RAPEX)

Gouaches aux doigts — recall A12/03374/24

EU Safety Gate (RAPEX) · France · 2024-12-06 · Serious risk

Machine-translated with AI — the facts come from the issuing authority’s own notice (linked on this page); this language version was translated automatically by an AI model and is not reviewed. The original-language notice is authoritative. How we use AI →
Agency
EU Safety Gate (RAPEX)
Recall identifier
A12/03374/24
Date of alert
2024-12-06
Country / jurisdiction
France
Risk level
Serious risk
Risk type
Chemical
Brand
Mes belles couleurs
Product category
Toys
Product type
Finger paint
Barcode (EAN/GTIN)
3760002573915
Reported risk: The white, blue, red and black paintings have an excessive concentration of methylisothiazolinone (MI)(measured values: up to 2.8 mg/kg). MI causes severe skin burns and eye damage (if in contact with the eyes), and may cause an allergic skin reaction. In addition, the green painting has an excessive concentration of formaldehyde (measured value: 0.25 mg/kg). Formaldehyde is a skin sensitiser and can trigger allergic reactions and may cause cancer.
Action taken by the authority
Type of economic operator taking notified measure
Retailer
Category of measure
Recall of the product from end users
Date of entry into force
30/09/2024
Machine translation. This page was translated automatically from the English record we hold of the issuing authority’s notice. The English original is shown below and the authority’s own notice is linked above — both take precedence over this translation.

Product Name (original English): Gouaches aux doigts

Primary source: https://ec.europa.eu/safety-gate-alerts/screen/webReport/alertDetail/10092180

Verify each fact at the issuing agency before acting. Recall scope, affected lots, and remediation instructions may be updated by the agency after our last sync.

ProductGuru indexes recall and safety-alert records from ~30 public agency registries. We are not lawyers, regulators or product-safety consultants. This page restates what the named agency published; consult the primary source above (or qualified counsel in your jurisdiction) before any commercial, medical or safety decision.